Skip to main content
  • Important Safety Information
  • Full Prescribing Information
  • Medication Guide
  • Safe Returns
  • Información en Español
  • Instructions for Use
  • Healthcare Professionals
  • For US Patients
  • Select Indication
    • Moderate to severe PLAQUE PSORIASIS
    • Active PSORIATIC ARTHRITIS
  • Medication Guide Instructions for Use
  • Select Indication
    • Moderate to severe PLAQUE PSORIASIS
    • Active PSORIATIC ARTHRITIS

For US Patients

Tremfya® (guselkumab)

  • Important Safety Information
  • Full Prescribing Information
  • Medication Guide
  • Safe Returns
  • Información en Español
  • Instructions for Use
  • Healthcare Professionals
  • For US Patients
  • Select Indication
    • Moderate to severe PLAQUE PSORIASIS
    • Active PSORIATIC ARTHRITIS
Get Support

FOR LESS JOINT PAIN, STIFFNESS, 
AND SWELLING AT 24 WEEKS

INDIVIDUAL RESULTS MAY VARY

MOVE TOWARD 
TREMFYA®

Approved for adults 
with active psoriatic arthritis

FDA APPROVED SINCE 2017

Since its approval for moderate to severe plaque psoriasis in 2017, an estimated 45,000+ U.S. patients have started treatment with TREMFYA®.

TREMFYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).

And it's approved for the treatment of adults with active psoriatic arthritis. It selectively blocks interleukin 23 (IL-23), one of the key proteins thought to be responsible for symptoms of psoriatic arthritis.

TREMFYA® is the first and only medicine of its kind to be FDA approved to treat adults with active psoriatic arthritis.

TREMFYA® has been studied in patients. 
How TREMFYA® works has been demonstrated in laboratory studies.

RESULTS WITH TREMFYA® IN ACTIVE PSORIATIC ARTHRITIS

TREMFYA® can help reduce joint 
pain, stiffness, and swelling

In two medical studies, more than half of patients treated with TREMFYA® had at least a 20% improvement in active PsA symptoms (joint pain, swelling, stiffness) at 24 weeks compared to placebo.

Study participants with at least a 20% improvement in joint symptoms at 24 weeks

Individual results may vary.

FEWER PSORIATIC ARTHRITIS SYMPTOMS — MORE OF WHAT YOU USED TO DO

TREMFYA® can help reduce the joint pain, stiffness, and swelling that make everyday tasks harder to do. In medical studies, patients' ability to perform everyday activities was assessed in a questionnaire. At 24 weeks, people taking TREMFYA® showed an overall improvement in their ability to perform daily activities such as:

MORE THAN JOINT RELIEF — CLEARER SKIN, TOO

In medical studies at 24 weeks, an improvement in psoriasis skin plaques was seen in psoriatic arthritis patients treated with TREMFYA®.

FATIGUE WAS REDUCED IN SOME PATIENTS TREATED WITH TREMFYA®

In two medical studies at 24 weeks, the level of fatigue was assessed using a questionnaire to measure self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. Patients were asked to indicate their level of fatigue in the seven days prior.

Individual results may vary.

PAYING FOR TREMFYA®

2020 Janssen CarePath 
Savings Program

Learn how eligible commercial patients pay $5 per injection for TREMFYA®. Additional requirements may apply.

Heading

DISCOVER SUPPORT OPTIONS

Once you and your doctor have decided TREMFYA® is right for you, Janssen CarePath will help you find the resources you may need to get started and stay on track. We will give you information on your insurance coverage, potential out-of-pocket costs, and treatment support, and identify options that may help make your treatment 
more affordable.

START WITH TREMFYA®

SO SIMPLE TRIAL PROGRAM

The TREMFYA® So Simple Trial Program provides you with your first dose of TREMFYA® so you and your doctor can determine if it is right for you.

  • $0 COST
  • Connect with a Care Coordinator from Wegmans Specialty Pharmacy to enroll (you’ll get a call from 866-889-5660 within 24 hours of receipt of the trial program prescription). You’ll then get a call from a Care Coordinator in approximately 14-21 days from the date your medication is delivered to talk through insurance coverage. If this information is not available, a Care Coordinator will call you within 7 days to discuss next steps.
  • Shipment can be authorized within 3 business days after a prescription.*
  • This trial program is open to patients who have commercial insurance, government coverage, or no insurance coverage. However, there is no guarantee of continuous accessibility after the program ends.

Ask your healthcare provider how you can quickly get started with a 1-month trial at no cost.

This program is for medication only. Terms expire at the end of each calendar year and may change.

* Shipment date is dependent upon you opting in to the program and scheduling shipment.

SAFE RETURNS® NEEDLE DISPOSAL PROGRAM

If you've received approval from your doctor to inject at home and have been properly trained, you can use Safe Returns® as a simple, safe, and convenient way to dispose of your used syringes or the One-Press injector—at no cost to you. When you sign up, you'll receive an FDA-approved Safe Returns® plastic disposal container in the mail, along with easy-to-follow mail-back instructions.

FOR COMMERCIALLY 
INSURED PATIENTS

STAY ON TREMFYA®

If you have commercial insurance and your insurance coverage for TREMFYA® is approved

JANSSEN CAREPATH SAVINGS PROGRAM†

  • Eligible patients pay $5 per injection
  • $20,000 maximum program benefit per calendar year
  • See full program requirements at TREMFYA.JanssenCarePathSavings.com

ENROLL IN THE SAVINGS PROGRAM TODAY

Mobile Enrollment

Text “SAVINGS” to 56011

Enroll and receive an electronic Savings Program card that can be saved to your digital wallet on your iPhone or Android device

- OR -

Express Enrollment

Check your eligibility and enroll at MyJanssenCarePath.com/express

You will not be able to view and manage your Savings Program benefits until you create an account at MyJanssenCarePath.com.

†The Janssen CarePath Savings Program is unavailable to individuals who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Administration. This program is for medication only. Terms expire at the end of the program year and may change.

If your commercial insurance is delayed (>5 business days) or denied

JANSSEN LINK‡

  • You can receive TREMFYA® at no cost until you receive insurance coverage approval
  • See full program requirements at

JanssenCarePath.com/patient/TREMFYA/
starting-treatment

‡The Janssen Link program is unavailable to individuals who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Administration. This program is for medication only. Terms expire at the end of each program year and may change.

FOR PATIENTS WHO DON’T HAVE 
COMMERCIAL INSURANCE

If you are using a government-funded healthcare program or have no insurance coverage

  • Janssen CarePath can provide information about other resources that may be able to help with your out-of-pocket medication costs for TREMFYA®.
  • Visit JanssenPrescriptionAssistance.com for more information about affordability programs.

Visit JanssenCarePath.com/TREMFYA

Create a Janssen CarePath Account at MyJanssenCarePath.com 
where you can learn about your insurance coverage for TREMFYA®; if eligible, enroll in the Janssen CarePath Savings Program and manage program benefits; and sign up for treatment support.

Need help? Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday–Friday, 8:00 am to 8:00 pm ET.

MOVE TOWARD TREMFYA®

ASK YOUR DOCTOR ABOUT TREMFYA®

You can also download our patient 
brochure to learn more.

Download

Discover the immunological conditions that Janssen Immunology has expertise in treating, which include rheumatology, gastroenterology and dermatology.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TREMFYA®?

TREMFYA® is a prescription medicine that may cause serious side effects, including:

  • Serious Allergic Reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
    • fainting, dizziness, feeling lightheaded (low blood pressure)
    • swelling of your face, eyelids, lips, mouth, tongue or throat
    • trouble breathing or throat tightness
    • chest tightness
    • skin rash, hives
    • itching
  • Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®.

    Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

    • fever, sweats, or chills
    • muscle aches
    • weight loss
    • cough
    • warm, red, or painful skin or sores on your body different from your psoriasis
    • diarrhea or stomach pain
    • shortness of breath
    • blood in your phlegm (mucus)
    • burning when you urinate or urinating more often than normal

Do not take TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA®.

Before using TREMFYA®, tell your healthcare provider about all of your medical conditions, including if you:

  • have any of the conditions or symptoms listed in the section “What is the most important information I should know about TREMFYA®?”
  • have an infection that does not go away or that keeps coming back.
  • have TB or have been in close contact with someone with TB.
  • have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA®.
  • are pregnant or plan to become pregnant. It is not known if TREMFYA® can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if TREMFYA® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of TREMFYA®?

TREMFYA® may cause serious side effects. See “What is the most important information I should know about TREMFYA®?”

The most common side effects of TREMFYA® include: upper respiratory infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, and bronchitis.

These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects.

Use TREMFYA® exactly as your healthcare provider tells you to use it.

Please read the full Prescribing Information, including Medication Guide for TREMFYA®, and discuss any questions that you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

cp-82626v3

Requires Adobe® Reader®. Click here to download

WHAT IS TREMFYA® (guselkumab)?

TREMFYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).

TREMFYA® is a prescription medicine used to treat adults with active psoriatic arthritis.

Discover the immunological conditions that Janssen Immunology has expertise in treating, which include rheumatology, gastroenterology and dermatology.

Janssen

© Janssen Biotech, Inc. 2021.

This site is published by Janssen Biotech, Inc., which is solely responsible for its contents. The material on this site is intended only as informational or as an educational aid and it is not intended to be taken as medical advice. The ultimate responsibility for patient care resides with a healthcare professional.

This information is intended for the use of patients and caregivers in the United States and Puerto Rico only. Laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

Legal Notice | Privacy Policy | Contact Us

Do not sell my personal information

Last updated January 13, 2021.

  • Legal Notice
  • Privacy Policy
  • Contact Us
  • About Janssen Biotech, Inc.
  • Sitemap
  • Pregnancy Registry

Last updated January 13, 2021.

YOU ARE NOW LEAVING TREMFYA.COM

By clicking "OK" below, you will be taken to [extlink:external-url], a website that may contain links or references to other websites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every website you visit. Our Privacy Policy is located at tremfya.com/privacy-policy.

Your are solely responsible for your interactions with such websites.

OK CANCEL
X

ARE YOU A HEALTHCARE PROVIDER?

The information contained in this section of the site is intended for US healthcare professionals only.

Click on the appropriate button below.

YES NO
X

LET'S STAY IN TOUCH

Sign up to receive information about TREMFYA® (guselkumab)

Sign up now